Silo pharma's ptsd candidate spc-15 achieves positive safety milestone, paving way for accelerated clinical trials under 505(b)(2) pathway

Spc-15's intranasal spray formulation meets safety standards for clinical trial development sarasota, fl, aug. 19, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced positive bioanalytical and safety/toxicology results for its u.s. food and drug administration (fda)-requested 7-day large animal safety study of its lead asset spc-15. silo ceo eric weisblum commented, “overall, we believe the positive results of this study confirm that spc-15's formulation and spray profile meets the safety standards for clinical trials.
SILO Ratings Summary
SILO Quant Ranking